4d pharma (4d pharma) Capex-to-Operating-Income : 0.00 (As of Dec. 2021)

View and export this data going back to 2021. Start your Free Trial

What is 4d pharma Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

4d pharma's Capital Expenditure for the six months ended in Dec. 2021 was $-0.12 Mil. Its Operating Income for the six months ended in Dec. 2021 was $-17.75 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

4d pharma Capex-to-Operating-Income Historical Data

The historical data trend for 4d pharma's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma Capex-to-Operating-Income Chart

4d pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Capex-to-Operating-Income

Get a 7-Day Free Trial

4d pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
Capex-to-Operating-Income	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of 4d pharma's Capex-to-Operating-Income

For the Biotechnology subindustry, 4d pharma's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4d pharma's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4d pharma's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where 4d pharma's Capex-to-Operating-Income falls into.

4d pharma Capex-to-Operating-Income Calculation

4d pharma's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.27)	/	-35.278
	=	N/A

4d pharma's Capex-to-Operating-Income for the quarter that ended in Dec. 2021 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.116)	/	-17.745
	=	N/A

4d pharma (OTCPK:LBPWQ) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

4d pharma Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of 4d pharma's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

4d pharma (4d pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (OTCPK:LBPWQ) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ

Website

https://www.4dpharmaplc.com

4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.